HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management

Nature Reviews Clinical Oncology, Год журнала: 2022, Номер 19(5), С. 306 - 327

Опубликована: Фев. 1, 2022

Язык: Английский

---

Identification of host–pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank

Nature Communications, Год журнала: 2022, Номер 13(1)

Опубликована: Апрель 5, 2022

Certain infectious agents are recognised causes of cancer and other chronic diseases. To understand the pathological mechanisms underlying such relationships, here we design a Multiplex Serology platform to measure quantitative antibody responses against 45 antigens from 20 including human herpes, hepatitis, polyoma, papilloma, retroviruses, as well Chlamydia trachomatis, Helicobacter pylori Toxoplasma gondii, then assayed random subset 9695 UK Biobank participants. We find seroprevalence estimates consistent with those expected prior literature confirm multiple associations sociodemographic characteristics (e.g., lifetime sexual partners C. trachomatis), HLA genetic variants (rs6927022 Epstein-Barr virus (EBV) EBNA1 antibodies) disease outcomes (human papillomavirus-16 seropositivity cervical intraepithelial neoplasia, EBV sclerosis). Our accessible dataset is one largest incorporating diverse in prospective cohort offering opportunities improve our understanding host-pathogen-disease relationships significant clinical public health implications.

Язык: Английский

---

Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination

Nature Reviews Clinical Oncology, Год журнала: 2024, Номер 21(7), С. 522 - 538

Опубликована: Май 17, 2024

Язык: Английский

---

HPV-associated oropharyngeal cancer: in search of surrogate biomarkers for early lesions

Oncogene, Год журнала: 2024, Номер 43(8), С. 543 - 554

Опубликована: Янв. 8, 2024

The incidence of oropharyngeal cancer (OPSCC) has escalated in the past few decades; this largely been triggered by high-risk human papillomavirus (HPV). Early screening is needed for timely clinical intervention and may reduce mortality morbidity, but lack knowledge about premalignant lesions OPSCC poses a significant challenge to early detection. Biomarkers that identify individuals at high risk act as surrogate markers precancer these are limited only studies decipher multistep progression from HPV infection development. Here, we summarize current literature describing oral infection, persistence, tumor development oropharynx. We also examine key challenges hinder identification oropharynx discuss potential biomarkers precancer. Finally, evaluate novel strategies improve investigations biological process drives persistence OPSCC, highlighting new developments establishment genetic model + vivo models mimic pathogenesis.

Язык: Английский

---

Oropharyngeal Cancer Incidence and Mortality Trends in All 50 States in the US, 2001-2017

JAMA Otolaryngology–Head & Neck Surgery, Год журнала: 2021, Номер 148(2), С. 155 - 155

Опубликована: Дек. 16, 2021

Importance

Oropharyngeal cancer (OPC) incidence is rising among men in the US. Comprehensive assessments of nationwide trends OPC and mortality by demographics, tumor characteristics at diagnosis, geography are lacking.

Objective

We examined secular rates all 50 US states District Columbia (DC).

Design, Setting, Participants

In this cross-sectional study, we used Cancer Statistics data set to examine from 2001 through 2017. Observed incidence-based were evaluated using National Center for Health Surveillance Epidemiology End Results program, respectively. Data analysis was conducted January April 2021.

Results

Nationwide, 260 182 cases identified; 209 297 (80%) occurred men, 168 674 (65%) with regional stage, 142 068 (55%) Southeast Midwest regions, during Incidence increased nationally 2.7% per year a notable (over 3% year) rise non-Hispanic White aged 65 years older. Overall, women, annual percentage change 0.5% (95% CI, −0.28% 1.22%). Among 3.1% 2.4% 3.8%), regional-stage nearly 2-fold. 1.0% 0.3% 1.7%). regions except Alaska, DC, Wyoming. most pronounced increases (more than 3.5% clustered regions. more 2% also concentrated 2.1% 3.2%) overall recent (from 2006 2017). contrast, −1.2% −2.5% 0.1%).

Conclusions Relevance

The findings study suggest that has continued increase US, rapid elderly population. concurrent troubling calls urgent improvements prevention. Distinct geographic patterns rises imply need improved targeted prevention as well future studies understand etiological reasons disparities.

Язык: Английский

---

Detection of circulating tumor human papillomavirus DNA before diagnosis of HPV‐positive head and neck cancer

International Journal of Cancer, Год журнала: 2022, Номер 151(7), С. 1081 - 1085

Опубликована: Март 9, 2022

Human papillomavirus (HPV), most commonly HPV16, causes a growing subset of head and neck squamous cell carcinomas (HNSCCs), including the overwhelming majority oropharynx in many developed countries. Circulating biomarkers for HPV-positive HNSCC may allow earlier diagnosis, with potential to decrease morbidity mortality. This case-control study evaluated whether circulating tumor HPV DNA (ctHPVDNA) is detectable prediagnostic plasma from individuals later diagnosed HNSCC. Cases were participants hospital-based research biobank archived collected ≥6 months before available archival tissue testing. Controls without cancer or HPV-related diagnoses, matched 10:1 cases by sex, race, age year collection. was detected using previously validated digital droplet PCR-based assay that quantifies tumor-tissue-modified viral (TTMV) DNA. Twelve patients median 68.5 years (range, 51-87 years) included. Ten (83.3%) had HPV16 DNA-positive tumors. ctHPV16DNA 3 10 (30%) HPV16-positive tumors, 7 (43%) The timing collection 19, 34 43 diagnosis. None 100 controls ctHPV16DNA. first report ctHPV16 at least several diagnosis patients. Further investigation as biomarker early warranted.

Язык: Английский

---

Current and Emerging Diagnostic, Prognostic, and Predictive Biomarkers in Head and Neck Cancer

Biomedicines, Год журнала: 2024, Номер 12(2), С. 415 - 415

Опубликована: Фев. 10, 2024

Head and neck cancers (HNC) are a biologically diverse set of that responsible for over 660,000 new diagnoses each year. Current therapies HNC require comprehensive, multimodal approach encompassing resection, radiation therapy, systemic therapy. With an increased understanding the mechanisms behind HNC, there has been growing interest in more accurate prognostic indicators disease, effective post-treatment surveillance, individualized treatments. This chapter will highlight commonly used studied biomarkers head squamous cell carcinoma.

Язык: Английский

---

Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI

Oral Oncology, Год журнала: 2020, Номер 108, С. 104736 - 104736

Опубликована: Июнь 2, 2020

Cancer of the oropharynx has attracted considerable attention in recent years given: (1) an increasing incidence selected populations over past three decades; (2) discovery human papillomavirus (HPV) infection as driver increase, opposed to traditional risk factors such tobacco (smoking and chewing) alcohol; (3) promise new prevention treatment strategies. As a result developments, International Agency for Research on (IARC) US National Institute (NCI), convened fourth Seminar meeting November 2018 focus this topic. This report summarizes proceedings: review science descriptive epidemiology, etiology, biology, genetics, early detection, pathology HPV-positive oropharyngeal cancer, formulation key research questions be addressed.

Язык: Английский

---

HPV and head and neck cancers: Towards early diagnosis and prevention

Tumour Virus Research, Год журнала: 2022, Номер 14, С. 200245 - 200245

Опубликована: Авг. 14, 2022

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide with an increasing trend of its incidence. Alcohol consumption, smoking, viral infections, such as mucosal high-risk (HR) human papillomaviruses (HPVs) are major risk factors for HNSCC development. In particular, HR HPVs mainly associated a subset oropharyngeal (OPSCC), while other head sites marginally affected by HPV infection. HPV16 frequently type HNSCC. contrast to cervix, no screening programs or identifiable pre-malignant lesions have been characterized HPV-related Therefore, identification general diagnostic algorithms biomarkers that could facilitate early diagnosis, disease evolution recurrence HPV-driven HNSCCs urgently needed. We herein review role in focus on epidemiology, biology, applied available body fluids tools HNSCCs.

Язык: Английский

---

Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium

Journal of Clinical Oncology, Год журнала: 2022, Номер 40(31), С. 3613 - 3622

Опубликована: Июнь 14, 2022

PURPOSE Seropositivity for the HPV16-E6 oncoprotein is a promising marker early detection of oropharyngeal cancer (OPC), but absolute risk OPC after positive or negative test unknown. METHODS We constructed an prediction model that integrates (1) relative odds serostatus and cigarette smoking from human papillomavirus (HPV) Cancer Cohort Consortium (HPVC3), (2) US population factor data National Health Interview Survey, (3) sex-specific rates mortality. RESULTS The nine HPVC3 cohorts included 365 participants with up to 10 years between blood draw diagnosis 5,794 controls. estimated 10-year seropositive males at age 50 was 17.4% (95% CI, 12.4 28.6) 60 27.1% 19.2 45.4). Corresponding 5-year estimates were 7.3% 14.4%, respectively. For females, 3.6% 2.5 5.9) 5.5% 3.8 9.2) 1.5% 2.7%, Over 30 years, result 49.9% 13.3% females would develop OPC. By contrast, risks among seronegative people very low, ranging 0.01% 0.25% depending on age, sex, status. CONCLUSION estimate substantial proportion individuals will OPC, 17%-27% 4%-6% 50-60 in United States. This high level may warrant periodic, minimally invasive surveillance serology test, particularly high-incidence regions. However, appropriate clinical protocol remains be established.

Язык: Английский

---